临床适当使用达那韦800毫克。

IF 1.6 4区医学 Q4 INFECTIOUS DISEASES

Southern African Journal of Hiv Medicine Pub Date : 2018-10-18 eCollection Date: 2018-01-01 DOI:10.4102/sajhivmed.v19i1.918

Michelle A Moorhouse, Sergio Carmona, Natasha Davies, Sipho Dlamini, Cloete van Vuuren, Thandekile Manzini, Moeketsi Mathe, Yunus Moosa, Jennifer Nash, Jeremy Nel, Yoliswa Pakade, Joana Woods, Gert van Zyl, Francesca Conradie, Francois Venter, Graeme Meintjes

{"title":"临床适当使用达那韦800毫克。","authors":"Michelle A Moorhouse, Sergio Carmona, Natasha Davies, Sipho Dlamini, Cloete van Vuuren, Thandekile Manzini, Moeketsi Mathe, Yunus Moosa, Jennifer Nash, Jeremy Nel, Yoliswa Pakade, Joana Woods, Gert van Zyl, Francesca Conradie, Francois Venter, Graeme Meintjes","doi":"10.4102/sajhivmed.v19i1.918","DOIUrl":null,"url":null,"abstract":"PREZISTA, in combination with low dose ritonavir (DRV/r) and with other antiretroviral medicines, is indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment experienced adult patients who are protease-inhibitor-naïve or after exclusion of darunavir resistance associated mutations (DRV-RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V). Genotypic or phenotypic testing should guide the use of DRV/r. (Prezista package insert)","PeriodicalId":49489,"journal":{"name":"Southern African Journal of Hiv Medicine","volume":"19 1","pages":"918"},"PeriodicalIF":1.6000,"publicationDate":"2018-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244068/pdf/","citationCount":"0","resultStr":"{\"title\":\"Appropriate clinical use of darunavir 800 mg.\",\"authors\":\"Michelle A Moorhouse, Sergio Carmona, Natasha Davies, Sipho Dlamini, Cloete van Vuuren, Thandekile Manzini, Moeketsi Mathe, Yunus Moosa, Jennifer Nash, Jeremy Nel, Yoliswa Pakade, Joana Woods, Gert van Zyl, Francesca Conradie, Francois Venter, Graeme Meintjes\",\"doi\":\"10.4102/sajhivmed.v19i1.918\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"PREZISTA, in combination with low dose ritonavir (DRV/r) and with other antiretroviral medicines, is indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment experienced adult patients who are protease-inhibitor-naïve or after exclusion of darunavir resistance associated mutations (DRV-RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V). Genotypic or phenotypic testing should guide the use of DRV/r. (Prezista package insert)\",\"PeriodicalId\":49489,\"journal\":{\"name\":\"Southern African Journal of Hiv Medicine\",\"volume\":\"19 1\",\"pages\":\"918\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2018-10-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244068/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Southern African Journal of Hiv Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4102/sajhivmed.v19i1.918\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Southern African Journal of Hiv Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4102/sajhivmed.v19i1.918","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Appropriate clinical use of darunavir 800 mg.

查看原文本刊更多论文

Appropriate clinical use of darunavir 800 mg.

PREZISTA, in combination with low dose ritonavir (DRV/r) and with other antiretroviral medicines, is indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment experienced adult patients who are protease-inhibitor-naïve or after exclusion of darunavir resistance associated mutations (DRV-RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V). Genotypic or phenotypic testing should guide the use of DRV/r. (Prezista package insert)

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Southern African Journal of Hiv Medicine 医学-病毒学

CiteScore

2.80

自引率

11.80%

发文量

审稿时长

>12 weeks

期刊介绍： The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and to support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice, and correspondence.